“TPX-0005 has demonstrated clinically meaningful and durable benefit in patients with ROS1 fusion-positive lung cancers and NTRK fusion-positive tumors,” said Alexander Drilon, M.D., a key investigator in the TRIDENT-1 Study and Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center. “I continue to be encouraged by the preliminary antitumor activity … Continue reading TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study
NICE have published a guidance for Pfizer’s Xalkori drug to treat ROS1-postivie non-small cell lung cancer has been made available via the Cancer drugs fund. Head of Oncology at Pfizer UK Craig Eagle commented on the news, “The decision to make the drug available is good news for patients in England. We are committed to … Continue reading Pfizer new lung cancer drug is successful for funding.
Since I’ve been holding steady on my treatment, I haven’t needed access to a clinical trial yet. However, clinical trials may become essential to my survival, and I’m already concerned about getting into them when I need help the most. I often hear scientists ask, “how can we increase patient participation in clinical trials so … Continue reading The Unnecessary Cruelty of Clinical Trials by: Lisa Goldman
For two weeks in August, 2015, I had whole brain radiation therapy. Ten days of being locked to a table for seven-minute sessions intended to slow or stop the growth of the metastatic cancer in my brain. During treatments I saw blue lights and smelled chlorine, neither of which were in the room, a testament … Continue reading My Hair is Coming Back!
Well, I did it again. During the first hour of the first day of registration for the 2016 Pan Mass Challenge, I went to their website and paid the $235 fee to register. I’m not sure why I was in such a hurry to do so. Happily there were some donors who seemed in a … Continue reading Riding the PMC